Bugs & Drugs
I found that I was losing the plot about what was where! Here’s my quick guide to priority pathogens (just below) and pipeline reviews. Note in particular that a comparative Summary of the priority pathogens lists is provided. For my summary of incentives to support this pipeline, see this webpage. Corrections and amends gratefully received.
Priority Pathogen / Threat Lists
- By my count, five priority pathogen lists have been proposed / published to date:
- India 2021: Newsletter is here, report is here.
- CDC 2019: Newsletter is here, report itself is here.
- WHO 2017: Newsletter is here, report itself is here.
- CDC 2013: Report itself is here.
- ESKAPE list 2008-9: This is the grandfather/mother of them all! The original papers are here:
- (link) Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis. 2008;197(8):1079-81.
- (link) Boucher HW et al. Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America. Clinical Infectious Diseases. 2009;48(1):1-12
To help you keep them organized, a comparative summary of the priority pathogen lists as a PowerPoint deck is here.
- Please also see this newsletter for a further discussion of the priority pathogen lists as well as the idea of first- vs. best-in-class.
Pipeline Reviews
- Reviews by WHO
- WHO 2020: My newsletter is here (and includes a video chat with Peter Beyer, one of the key drivers of the report). The review itself is here.
- WHO 2019: My newsletter is here, commentary by WHO staff is here, the pre-clinical pipeline review is here and is supported by a data-mining interface here; the clinical pipeline review is here.
- WHO 2017: Newsletter is here, report is here, and manuscript about the review is here.
- Reviews by the Pew Trusts (all updated as of March 2021; see also this newsletter)
- Independent pipeline reviews
- Clinical pipeline: Theuretzbacher et al. Nat Rev Microbiol 2020 (https://doi.org/10.1038/s41579-020-0340-0) is an extended commentary on the current pipeline by the group who did the WHO 2019 review.
- Clinical pipeline: Butler and Paterson, J Antibiot 2020 https://doi.org/10.1038/s41429-020-0291-8: Not open access, but you can view it online here.
- Commercial view of recently approved drugs: Alan Carr 2020: Newsletter is here. Alan’s regularly updated summary analyzes products approved in the US since 2009.
- Non-traditional products: Theuretzbacher and Piddock, Cell Host Microb 2019 (https://doi.org/10.1016/j.chom.2019.06.004) and Rex et al. Nat Commun 2019, https://doi.org/10.1038/s41467-019-11303-9: Focused reviews and discussions of non-traditional products. Go here for a newsletter about these two papers.
- Preclinical pipeline: Theuretzbacher et al. Nat Rev Microbiol 2019 (https://www.nature.com/articles/s41579-019-0288-0) surveys 400+ active preclinical programs.
- Access- and Stewardship-focused reviews
Pull incentives in the EU / Statements by Commissioner Kyriakides
Dear All, Stella Kyriakides, the European Commissioner for Health and Food Safety, made some really interesting statements before the European Parliament’s health committee (ENVI) on Thursday of last week (22 April). Per this Exchange of Views on the EP’s multimedia center and this news report, here are some highlights: In the Exchange of Views at 00:03:44, she said: “Later
Global views: UN Dialogue, WHO @ ECCMID, JPIAMR/JAMRAI (Christine Ardal video)
Dear All, Three global conversations to put on your listen-to-this list! One is this coming week, one is during ECCMID, and one is a video you can listen to now! First up and happening in just a few days on Thursday 29 Apr (10a-6p EST), please mark your calendar for a UN General Assembly High-Level interactive
